Skip to content

The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study)

The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01466426
Acronym
PETVET
Enrollment
40
Registered
2011-11-08
Start date
2011-11-30
Completion date
2014-06-30
Last updated
2014-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolic Disease

Keywords

Venous thromboembolic disease, Deep veinous thrombosis, Pulmonary embolism

Brief summary

This pilot study aims at validating 18F-flourodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the detection and characterization of venous thromboembolism (VTE) in the entire human body, especially deep venous thrombosis (DVT) and pulmonary embolism (PE). On completion of this study the investigators will hopefully be able to demonstrate the importance of functional/molecular imaging technique in managing patients with this common and potentially fatal disorder.

Detailed description

Acute DVT and PE are common and serious conditions. Highly effective treatment (most often anticoagulant agents) is available for acute VTE, but it is associated with potentially dangerous side effects. In addition, DVT and PE are just two manifestations of VTE, which can occur everywhere in the human organism. An underlying disease (i.e. cancer) is often a key factor in developing VTE. Commonly used diagnostic imaging techniques in DVT and PE have a fair diagnostic accuracy, but do not address other important aspects of the disease. In contrast to this, FDG-PET/CT has the potential to contribute in VTE diagnosis by * Differentiate between acute and chronic VTE * Screening of the entire body for VTE (e.g. the pelvis where normal imaging techniques fail) * Early diagnosis of underlying disease (e.g. cancer, with the possibility of early treatment) This is a pilot study with the above mentioned objectives, and is part of a larger study addressing other aspects of FDG-PET/CT in VTE. The investigators believe that their hypothesis that FDG-PET/CT imaging may introduce a new approach for detecting thrombi anywhere in the body, particularly in the venous system including the pelvis and the calves, will add a new dimension in treating patients with suspected PE. This technology will only detect acute thrombi and not chronic thrombi that no longer have activity, which will obviate unnecessary treatment in this population.

Interventions

None listed

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Positive or negative diagnosis of VTE (DVT/PE) * Age ≥ 50 years * Informed consent obtained * Symptoms \< 1 week

Exclusion criteria

* Pregnant or lactating women * Foreign language patients with a need for an interpreter * Previous DVT or PE * Known malignancy

Design outcomes

Primary

MeasureTime frameDescription
Proof-of-conceptDuring diagnostic workupSimple assessment of scans - positive or negative in the relevant patient categories

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026